Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Safety and effectiveness of monthly intravenous ibandronate injections in a prospective, postmarketing, and observational study in Japanese patients with osteoporosis.

Takeuchi Y, Hashimoto J, Nishida Y, Yamagiwa C, Tamura T, Atsumi A.

Osteoporos Sarcopenia. 2018 Mar;4(1):22-28. doi: 10.1016/j.afos.2018.01.001. Epub 2018 Feb 17.

2.

Effectiveness of monthly intravenous ibandronate injections in a real-world setting: Subgroup analysis of a postmarketing observational study.

Takeuchi Y, Hashimoto J, Kakihata H, Nishida Y, Kumagai M, Yamagiwa C.

Osteoporos Sarcopenia. 2019 Mar;5(1):11-18. doi: 10.1016/j.afos.2019.02.002. Epub 2019 Mar 14.

3.

Clinical efficacy and safety of monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in Japanese patients with primary osteoporosis.

Nakamura T, Ito M, Hashimoto J, Shinomiya K, Asao Y, Katsumata K, Hagino H, Inoue T, Nakano T, Mizunuma H; MOVEST Study Group.

Osteoporos Int. 2015 Nov;26(11):2685-93. doi: 10.1007/s00198-015-3175-1. Epub 2015 May 23.

4.

Efficacy and safety of monthly ibandronate in men with low bone density.

Orwoll ES, Binkley NC, Lewiecki EM, Gruntmanis U, Fries MA, Dasic G.

Bone. 2010 Apr;46(4):970-6. doi: 10.1016/j.bone.2009.12.034. Epub 2010 Jan 6.

PMID:
20060082
5.

Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg.

Epstein S, Jeglitsch M, McCloskey E.

Curr Med Res Opin. 2009 Dec;25(12):2951-60. doi: 10.1185/03007990903361307. Review.

PMID:
19835464
6.

Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.

Emkey R, Delmas PD, Bolognese M, Borges JL, Cosman F, Ragi-Eis S, Recknor C, Zerbini CA, Neate C, Sedarati F, Epstein S.

Clin Ther. 2009 Apr;31(4):751-61. doi: 10.1016/j.clinthera.2009.04.018.

PMID:
19446148
7.

Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial.

Hakala M, Kröger H, Valleala H, Hienonen-Kempas T, Lehtonen-Veromaa M, Heikkinen J, Tuomiranta T, Hannonen P, Paimela L; ONCE trial group.

Scand J Rheumatol. 2012 Aug;41(4):260-6. doi: 10.3109/03009742.2012.664647.

PMID:
22803768
8.

Effectiveness of monthly intravenous ibandronate on the low responders to oral bisphosphonate: the MOVEMENT study.

Hagino H, Sakai A, Ikeda S, Imanishi Y, Tsurukami H, Nakajo S, Miyakoshi N.

J Bone Miner Metab. 2019 May 16. doi: 10.1007/s00774-019-01005-z. [Epub ahead of print] Erratum in: J Bone Miner Metab. 2019 Jul 27;:.

PMID:
31098670
9.

Effect of monthly intravenous ibandronate injections on vertebral or non-vertebral fracture risk in Japanese patients with high-risk osteoporosis in the MOVER study.

Ito M, Tobinai M, Yoshida S, Hashimoto J, Nakamura T.

J Bone Miner Metab. 2017 Jan;35(1):58-64. doi: 10.1007/s00774-015-0723-x. Epub 2015 Nov 27.

PMID:
26614597
10.

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

Chesnut CH 3rd, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD; Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE).

J Bone Miner Res. 2004 Aug;19(8):1241-9. Epub 2004 Mar 29.

11.
12.

Safety and effectiveness of daily teriparatide in a prospective observational study in patients with osteoporosis at high risk of fracture in Japan: final report.

Nishikawa A, Ishida T, Taketsuna M, Yoshiki F, Enomoto H.

Clin Interv Aging. 2016 Jul 6;11:913-25. doi: 10.2147/CIA.S107285. eCollection 2016.

13.

Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss.

McClung MR, Bolognese MA, Sedarati F, Recker RR, Miller PD.

Bone. 2009 Mar;44(3):418-22. doi: 10.1016/j.bone.2008.09.011. Epub 2008 Oct 7.

PMID:
18950736
14.

Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.

McClung MR, Wasnich RD, Recker R, Cauley JA, Chesnut CH 3rd, Ensrud KE, Burdeska A, Mills T; Oral Ibandronate Study Group.

J Bone Miner Res. 2004 Jan;19(1):11-8.

15.

Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis.

Nakamura T, Nakano T, Ito M, Hagino H, Hashimoto J, Tobinai M, Mizunuma H; MOVER Study Group.

Calcif Tissue Int. 2013 Aug;93(2):137-46. doi: 10.1007/s00223-013-9734-6. Epub 2013 May 5.

16.

Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis.

Recker R, Stakkestad JA, Chesnut CH 3rd, Christiansen C, Skag A, Hoiseth A, Ettinger M, Mahoney P, Schimmer RC, Delmas PD.

Bone. 2004 May;34(5):890-9.

PMID:
15121021
17.
18.

Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE.

Chesnut CH, Ettinger MP, Miller PD, Baylink DJ, Emkey R, Harris ST, Wasnich RD, Watts NB, Schimmer RC, Recker RR.

Curr Med Res Opin. 2005 Mar;21(3):391-401.

PMID:
15811208
19.

Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review.

Rossini M, Viapiana O, Gatti D, Adami S.

Clin Ther. 2009 Jul;31(7):1497-510. doi: 10.1016/j.clinthera.2009.07.018. Review.

PMID:
19695399
20.

Ibandronate: A Review in Japanese Patients with Osteoporosis.

Keating GM.

Drugs Aging. 2016 Apr;33(4):295-303. doi: 10.1007/s40266-016-0360-7. Review.

PMID:
26915075

Supplemental Content

Support Center